Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 14/20 | 0.68 |
| ▸ | NSD2 | O96028 | 5/20 | 0.56 |
| ▸ | WHR1 | P49842 | 1/20 | 0.50 |
| ▸ | KDM1A | O60341 | 2/20 | 0.49 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.49 |
| ▸ | EHMT1 | Q9H9B1 | 6/20 | 0.49 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1428017 | 0.94 | EHMT2 (0.74) | EHMT2NSD2WHR1KDM1ARCOR1 | |
| SCHEMBL15280234 | 0.87 | EHMT2 (0.74) | EHMT2NSD2WHR1KDM1ARCOR1 | |
| SCHEMBL12390464 | 0.87 | NSD2 (0.70) | EHMT2NSD2WHR1KDM1ARCOR1 | |
| SCHEMBL15280412 | 0.84 | EHMT2 (0.68) | EHMT2NSD2WHR1KDM1ARCOR1 | |
| SCHEMBL1748471 | 0.84 | NSD2 (0.76) | EHMT2NSD2WHR1KDM1ARCOR1 | |
| SCHEMBL29613418 | 0.84 | NSD2 (0.76) | EHMT2NSD2WHR1KDM1ARCOR1 | |
| SCHEMBL15280237 | 0.82 | EHMT2 (0.66) | EHMT2NSD2KDM1ARCOR1EHMT1 | |
| SCHEMBL29809532 | 0.81 | EHMT2 (1.00) | EHMT2NSD2EHMT1 | |
| SCHEMBL15280254 | 0.81 | EHMT2 (1.00) | EHMT2NSD2EHMT1 | |
| SCHEMBL3323652 | 0.81 | EHMT2 (0.81) | EHMT2NSD2EHMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324226-B2 | Therapeutic oxy-phenyl-aryl compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2012-12-04 | — | — | US | disclosed |
| EP-2227460-B1 | THERAPEUTIC OXY-PHENYL-ARYL COMPOUNDS AND THEIR USE | CANCER REC TECH LTD (GB) | 2012-06-20 | — | — | EP | disclosed |
| US-20110201592-A1 | Therapeutic Oxy-Phenyl-Aryl Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-08-18 | — | — | US | disclosed |
| EP-2227460-A1 | THERAPEUTIC OXY-PHENYL-ARYL COMPOUNDS AND THEIR USE | Cancer Research Technology Limited (GB) | 2010-09-15 | — | — | EP | disclosed |
| WO-2009053694-A1 | THERAPEUTIC OXY-PHENYL-ARYL COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201592-A1 | Therapeutic Oxy-Phenyl-Aryl Compounds and Their Use | CHEK2, CHEK1, PLK1 | EHMT2 1320/4885NSD2 2599/4885WHR1 1035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.